Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Relative Vaccine Effectiveness of a Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine Booster Dose Against the Omicron Variant

Clinical Infectious Diseases(2022)10.1093/cid/ciac328Source: DataRank Database

Relative Vaccine Effectiveness of a Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine Booster Dose Against the Omicron Variant is a research paper published in Clinical Infectious Diseases (2022). On theSindex it has a DataRank of 0. It has been cited 48 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access48 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 4.44)OA: hybridTopics (63)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (5)

Victor B. Talisa ORCID,Obaid S. Shaikh ORCID,Saad B. Omer ORCID,Florian Mayr ORCID,Adeel A. Butt ORCID

Live enrichment

PubMed:35511586 PMC:PMC11487159 OpenAlex:https://openalex.org/W4226307229

VA Informatics and Computing Infrastructure

Grant: VA HSR RES 13-457

National Institutes of Health

Grant: K23GM132688

National Institutes of Health

Grant: 5K23GM132688-02

A precision medicine framework to improve long-term outcomes in Sepsis Survivors

Department of Veterans Affairs

VA Pittsburgh Healthcare System

FWCI

4.44

Citation Percentile

1.0%

Citation Trend

2022

2023

2024

2025

2026

hybridLicense: public-domain

journalhttps://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciac328/44298168/ciac328.pdf

publisherhttps://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciac328/44298168/ciac328.pdf

publisherhttps://academic.oup.com/cid/article-pdf/75/12/2161/59836175/ciac328.pdf

journalhttps://doi.org/10.1093/cid/ciac328

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35511586

Fields of Study

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections StudiesCOVID-19 Clinical Research Studies03 medical and health sciences0302 clinical medicineHumansSARS-CoV-22019-nCoV Vaccine mRNA-1273BNT162 VaccineRetrospective StudiesVaccine EfficacyCOVID-19VaccinesRNARNA, MessengerCOVID-19 VaccinesSARS-CoV-2 variants

MeSH Terms

COVID-19SARS-CoV-2COVID-19 VaccinesVaccine EfficacyBNT162 Vaccine2019-nCoV Vaccine mRNA-1273HumansRetrospective StudiesRNARNA, MessengerVaccines

Keywords

MedicineBooster (rocketry)VirologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Booster doseCoronavirus disease 2019 (COVID-19)Coronavirus2019-20 coronavirus outbreakRespiratory systemMessenger RNASevere acute respiratory syndrome coronavirusImmunologyVirusGeneInternal medicineInfectious disease (medical specialty)TiterDiseaseBiologyOutbreakVaccine EffectivenessBoosterSars-cov-2Delta VariantOmicron VariantVaccinesCOVID-19 VaccinesVaccine EfficacyCOVID-19HumansRNARNA, MessengerBNT162 Vaccine2019-nCoV Vaccine mRNA-1273Retrospective Studies

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being